BACKGROUND: Treatment of multiple myeloma has changed significantly over the past several years with clinical trials reporting superior survival results using newer agents. Previous work has shown that the survival rate has improved for younger, but not older, patients with myeloma. Here, we update survival estimates for patients with myeloma in the early 21st century to determine whether continued improvement can be seen on a population level and whether or not it now extends to older patients. METHODS: Using period analysis to examine data from the Surveillance, Epidemiology, and End Results database, we estimate changes in the 5- and 10-year relative survival rates (RSRs) from 1998-2002 to 2003-2007. RESULTS: The 5- and 10-year RSRs have improved for patients with myeloma overall, from 32.8% and 15% in 1998-2002 to 40.3% and 20.8%, respectively, in 2003-2007. The greatest improvements were observed for patients aged 15-44 years, with 5- and 10-year RSRs reaching >70% and ~50%, respectively, but improvements were also seen for patients aged >70 years. CONCLUSION: Overall, survival continues to improve for patients with myeloma, including older patients, suggesting that newer treatment options continue to make a population-wide impact.
BACKGROUND: Treatment of multiple myeloma has changed significantly over the past several years with clinical trials reporting superior survival results using newer agents. Previous work has shown that the survival rate has improved for younger, but not older, patients with myeloma. Here, we update survival estimates for patients with myeloma in the early 21st century to determine whether continued improvement can be seen on a population level and whether or not it now extends to older patients. METHODS: Using period analysis to examine data from the Surveillance, Epidemiology, and End Results database, we estimate changes in the 5- and 10-year relative survival rates (RSRs) from 1998-2002 to 2003-2007. RESULTS: The 5- and 10-year RSRs have improved for patients with myeloma overall, from 32.8% and 15% in 1998-2002 to 40.3% and 20.8%, respectively, in 2003-2007. The greatest improvements were observed for patients aged 15-44 years, with 5- and 10-year RSRs reaching >70% and ~50%, respectively, but improvements were also seen for patients aged >70 years. CONCLUSION: Overall, survival continues to improve for patients with myeloma, including older patients, suggesting that newer treatment options continue to make a population-wide impact.
Authors: Hervé Avet-Loiseau; Rafael Fonseca; David Siegel; Meletios A Dimopoulos; Ivan Špička; Tamás Masszi; Roman Hájek; Laura Rosiñol; Vesselina Goranova-Marinova; Georgi Mihaylov; Vladimír Maisnar; Maria-Victoria Mateos; Michael Wang; Ruben Niesvizky; Albert Oriol; Andrzej Jakubowiak; Jiri Minarik; Antonio Palumbo; William Bensinger; Vishal Kukreti; Dina Ben-Yehuda; A Keith Stewart; Mihaela Obreja; Philippe Moreau Journal: Blood Date: 2016-07-20 Impact factor: 22.113
Authors: Gunjan L Shah; Aaron N Winn; Pei-Jung Lin; Andreas Klein; Kellie A Sprague; Hedy P Smith; Rachel Buchsbaum; Joshua T Cohen; Kenneth B Miller; Raymond Comenzo; Susan K Parsons Journal: Biol Blood Marrow Transplant Date: 2015-05-30 Impact factor: 5.742
Authors: Michael G Brandel; Ali A Alattar; Brian R Hirshman; Xuezhi Dong; Kate T Carroll; Mir Amaan Ali; Bob S Carter; Clark C Chen Journal: J Neurooncol Date: 2017-04-24 Impact factor: 4.130
Authors: Meletios A Dimopoulos; Katja C Weisel; Kevin W Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Philippe Moreau; Anne Banos; Albert Oriol; Laurent Garderet; Michele Cavo; Valentina Ivanova; Adrian Alegre; Joaquin Martinez-Lopez; Christine Chen; Andrew Spencer; Stefan Knop; Nizar J Bahlis; Christoph Renner; Xin Yu; Kevin Hong; Lars Sternas; Christian Jacques; Mohamed H Zaki; Jesus F San Miguel Journal: Haematologica Date: 2015-08-06 Impact factor: 9.941